Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000956 · ClinicalTrials.gov registry record · Phase 1

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
25
Enrollment target
2
Study locations

NCT00000956: Completed Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00000956 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 25 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000956, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target
2
Study locations

Study Summary

To evaluate the safety and immune response to 640 and 1280 mcg HIV-1 recombinant envelope glycoprotein gp160. To evaluate the duration of antibody response and its relationship to dose and frequency of inoculation. Evaluation of previous patients who received doses of 40 or 80 mcg gp160 vaccine indicates that, although serum anti-gp160 antibody responses were detected, the level and duration of those responses were limited. A preliminary observation suggests that weak functional antibody responses may develop following the 18 month booster of 40 or 80 mcg; therefore, a dose of gp160 vaccine having potentially greater immunogenicity is of particular interest.

Conditions Studied

HIV Infections

Interventions

  • BIOLOGICAL gp160 Vaccine (MicroGeneSys)

Study Locations (2)

Missouri

  • St. Louis Univ. School of Medicine AVEG - St Louis

Pennsylvania

  • JHU AVEG - Pittsburgh

Trial Details

FieldValue
Enrollment Target 25 participants
Est. Completion 1993-03
Phase Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

What the finished NCT00000956 record still lists

NCT00000956 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which gp160 Vaccine (MicroGeneSys) is the first listed.

NCT00000956 reports a single indexed study location in Missouri, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00000956 about?

NCT00000956 is a clinical study titled "A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160". To evaluate the safety and immune response to 640 and 1280 mcg HIV-1 recombinant envelope glycoprotein gp160. To evaluate the duration of antibody response and its relationship to dose and frequency of inoculation. Evaluation of previous patients who received doses of 40 or 80 mcg gp160 vaccine ind...

What is the current status of trial NCT00000956?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. Estimated completion is 1993-03.

What conditions does trial NCT00000956 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00000956?

The interventions under investigation include: gp160 Vaccine (MicroGeneSys) (BIOLOGICAL).

Who is sponsoring clinical trial NCT00000956?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000956 being conducted?

This trial has 2 study locations across Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00000956's enrollment target sits among peer trials

25 461st of 542 higher than 74 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Related registry views

Source: ClinicalTrials.gov NCT00000956, the US trial registry maintained by the National Library of Medicine. NCT00000956 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.